Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alphabet Inc Class A (GOOGL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Alphabet Inc Class ATrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Alphabet Inc Class A vs Recursion Pharmaceuticals Inc — how do they compare? Alphabet Inc Class A trades at $341.55 (market cap $4.20T), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Alphabet Inc Class A is far larger — about 2320.4× Recursion Pharmaceuticals Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

GOOGLRXRX
Market Cap
$4.20T$1.81B
Sector
MediaHealth
52-Week High
$402.62$6.79
52-Week Low
$199.32$2.84
Enterprise Value
$4.09T$1.33B
Dividend Yield
0.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alphabet Inc Class A

Alphabet (GOOGL) is trading at $341.48, down 4.49% over the past 24 hours, with a bearish technical signal. The company demonstrates strong fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 85% analyst buy rating support the positive outlook, though technical indicators show near-term pressure with support at $341 and resistance at $350.

GOOGL presents a compelling long-term investment opportunity with robust profitability (54.77% net margin) and AI-driven growth potential, though investors face near-term technical weakness and regulatory risks. The consensus price target of $426.28 implies significant upside from current levels, supported by strong cash flow generation and strategic AI investments.

Recursion Pharmaceuticals Inc

RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.

Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alphabet Inc Class A

Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.

Read more on GOOGL

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX